Clinical effects and safety of ferric carboxymaltose in pregnancy: An Indian real‐life experience. Issue 10 (2nd August 2021)

• Record Type: Journal Article
• Authors: Gupte, Sanjay A.; Venkataraman, Gayatri; Shah, Aarti S.; Mudholkar, Aparna S.; Jangam, Shweta M.
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 47:Issue 10(2021)
• Page Start: 3464
• Page End: 3470
• Publication Date: 2021-08-02
• Subjects: anemia -- ferric carboxymaltose -- India -- iron deficiency -- pregnancy; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.14956
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Background: There is limited clinical evidence of ferric carboxymaltose injection (FCM) usage in Indian pregnant women. We assessed the efficacy and safety of FCM in Indian pregnant women with moderate‐to‐severe anemia. Methods: Single‐center, retrospective, observational data collection was conducted at a tertiary care research institute. Data of pregnant women with anemia who received FCM in their second and third trimester was retrieved and analyzed for hematological parameters at baseline and at 4 ± 2 weeks. Neonatal outcomes were also assessed. Adverse events and other safety parameters were noted. Results: Data of 271 patients was retrieved and analyzed for safety and data for 168 patients analyzed for efficacy. A significant increase in hemoglobin was noted with FCM in 4 weeks (1.25 g/dL; p < 0.001). Patients with severe anemia reported an increase in hemoglobin of 4.23 g/dL ( p = 0.01). Patients receiving FCM in the second trimester noted a significant increase in hemoglobin of 1.74 g/dL ( p < 0.001). A significant increase in hemoglobin was noted as early as 20 days ( p < 0.001) and also in patients receiving FCM after 34 weeks ( p = 0.002). No adverse fetal or neonatal outcomes were observed. Adverse events noted in 4% of patients with itching and rash being most common. Continuous monitoring of blood pressure, heart rate, and oxygen saturation for 40 min during and after FCM administration reported no deterioration or negative safety signal. Conclusion: FCM corrects anemia in all subsets of Indian pregnant women and supports evidence of efficacy and safety. Continuous monitoring of vital parameters during FCM infusions supports its excellent safety.